echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Genetron Health brings 22 new research results in the field of cancer to the 2021 American Association for Cancer Research Annual Meeting

    Genetron Health brings 22 new research results in the field of cancer to the 2021 American Association for Cancer Research Annual Meeting

    • Last Update: 2021-07-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com














    Numbering

    topic

    1464

    Enrichment and screening of LFS patients by analyzing TP53 germline mutations of


    2252

    Genome profiling of thymic carcinoma identifies putative driver mutations in the NF-


    2557

    Germline mutation landscape in a large cohort of Chines pancreatic cancer patients

    0803

    Molecular diagnosis and immunotherapy of a rare lung carcinoma patient associated


    0422

    Sequential targeted therapy and immunotherapy of a BRAF positive metastatic
    melanoma patient with BRAF inhibitor vemurafenib, MEK inhibitor cobimetnib and a
    novel PD-1 antibody Sintilimab

    2183

    Genomic profiling of small bowel adenocarcinoma reveals targetable mutations in
    multiple signaling pathways

    2217

    More somatic mutations can be detected in cerebrospinal fluid ctDNA of NSCLC
    patients with brain metastases

    2182

    Evaluation of somatic and germline mutations in ampullary carcinoma reveals
    actionable targets in multiple signaling pathways

    1209

    An effective treatment for recurrent and inoperable anaplastic thyroid carcinoma
    using sintilimab and anlotinib: a case report

    1681

    Correlation of BRCA1/2 mutations with response to immune checkpoint inhibitors in
    colorectal cancer

    1641

    The predictive values ​​of ARID1A mutations for response to immune checkpoint
    inhibitors are varied in different types of solid tumors

    1639

    Correlation of KMT2C/D loss-of-function mutations with PD-L1 expression and
    response to immune checkpoint inhibitors in solid tumors

    1640

    Correlations of DNA damage response gene alterations with response to immune
    checkpoint inhibitors are different in solid tumors

    2288

    Identification of gene fusions in soft tissue sarcoma improved by integrative DNA
    and RNA sequencing

    2163

    Molecular characteristics of CDK4 and/or MDM2 amplification in Chinese soft tissue
    sarcoma (STS) patients

    0625

    Co-amplification of CDK4 and MDM2 plus HMGA2 fusion in a patient with myogenic
    differentiation dedifferentiated liposarcoma

    2223

    Distinct genomic features of cutaneous, acral and mucosal melanomas in a Chinese
    retrospective cohort

    2216

    Exploration of the genomic features of pan-neuroendocrine tumors in a Chinese
    retrospective analysis

    2215

    Landscape of RET fusion identified by next–generation sequencing in a Chinese
    multi-cancer retrospective analysis

    1199

    Mosaic KRAS G12S mutation associates with poor outcome in papillary thyroid
    carcinoma: A case report

    2080

    Tumor microsatellite instability detection method using paired tumor-normal
    sequence data

    2313

    The characteristics of ERBB2 exon 20 insertion in a large cohort of Chinese NSCLC
    patients

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.